Loading
A phase 3 trial of Anlotinib, Penpulimab in hepatocellular carcinoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. is a phase 3 interventional study registered as NCT05862337 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 480 participants planned, started 2023-05-10 and due to reach its primary completion in 2024-08. Interventions recorded: Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Penpulimab, Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Penpulimab, Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Penpulimab, Sino Biopharmaceutical (Chia Tai Tianqing), Immune checkpoint inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors.